Johnson & Johnson reported positive Phase 3 results for Tecvayli in an earlier‑line multiple myeloma setting, with survival outcomes supporting plans to expand use beyond later‑line indications. The MajesTEC‑9 study enrolled patients earlier in the disease course and showed favorable survival signals consistent with the company’s push into earlier treatment lines. The readout strengthens Tecvayli’s positioning as a competitive BCMA‑targeted therapy and supports regulatory and commercial strategies to broaden indications. J&J now faces sequencing and access questions as payers and clinicians weigh adoption against existing standards. Investors and competitors will watch subsequent regulatory filings and long‑term follow‑up to assess durability and safety in broader patient populations.